COVID-19, Angiotensin Receptor Blockers, and the Brain.
作者信息
Saavedra Juan M
机构信息
Department of Pharmacology and Physiology, Georgetown University Medical Center, 3900 Reservoir Road, NW, Washington, DC, 20057, USA.
出版信息
Cell Mol Neurobiol. 2020 Jul;40(5):667-674. doi: 10.1007/s10571-020-00861-y. Epub 2020 May 8.
Abstract
摘要
相似文献
1
COVID-19, Angiotensin Receptor Blockers, and the Brain.
Cell Mol Neurobiol. 2020 Jul;40(5):667-674. doi: 10.1007/s10571-020-00861-y. Epub 2020 May 8.
2
Drugs and the renin-angiotensin system in covid-19.
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
3
Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers.
JAMA Cardiol. 2020 Jul 1;5(7):745-747. doi: 10.1001/jamacardio.2020.1282.
4
Angiotensin receptor blockers for the treatment of COVID-19 and its comorbidities.
Pharmacol Res. 2020 Sep;159:104958. doi: 10.1016/j.phrs.2020.104958. Epub 2020 May 28.
5
Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):335-337. doi: 10.1093/ehjcvp/pvaa074.
6
Controversy regarding ACE inhibitors / ARBs in COVID-19.
Rev Esp Cardiol (Engl Ed). 2020 Jun;73(6):516. doi: 10.1016/j.rec.2020.04.004. Epub 2020 Apr 15.
7
COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations.
Circulation. 2020 Jun 23;141(25):2042-2044. doi: 10.1161/CIRCULATIONAHA.120.047022. Epub 2020 Apr 13.
8
ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.
Crit Care. 2020 Jul 31;24(1):475. doi: 10.1186/s13054-020-03195-9.
9
EMA advice on renin-angiotensin system medicines during covid-19 pandemic.
Drug Ther Bull. 2020 Jun;58(6):85. doi: 10.1136/dtb.2020.000026. Epub 2020 Apr 15.
10
Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?
Anatol J Cardiol. 2020 Jul;24(1):19-20. doi: 10.14744/AnatolJCardiol.2020.73232.
引用本文的文献
1
Effects of COVID-19 on Synaptic and Neuronal Degeneration.
Brain Sci. 2023 Jan 12;13(1):131. doi: 10.3390/brainsci13010131.
2
Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective.
BMC Infect Dis. 2021 Feb 15;21(1):175. doi: 10.1186/s12879-021-05848-8.
3
A rapid review of the pathoetiology, presentation, and management of delirium in adults with COVID-19.
J Psychosom Res. 2021 Feb;141:110350. doi: 10.1016/j.jpsychores.2020.110350. Epub 2020 Dec 25.
4
The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning.
Alzheimers Dement. 2021 Jun;17(6):1056-1065. doi: 10.1002/alz.12255. Epub 2021 Jan 5.
5
Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?
Phytomedicine. 2021 May;85:153396. doi: 10.1016/j.phymed.2020.153396. Epub 2020 Oct 28.
6
A Review on the Neurological Manifestations of COVID-19 Infection: a Mechanistic View.
Mol Neurobiol. 2021 Feb;58(2):536-549. doi: 10.1007/s12035-020-02149-0. Epub 2020 Sep 26.
7
Candesartan could ameliorate the COVID-19 cytokine storm.
Biomed Pharmacother. 2020 Nov;131:110653. doi: 10.1016/j.biopha.2020.110653. Epub 2020 Aug 20.
8
Fractional diffusion on the human proteome as an alternative to the multi-organ damage of SARS-CoV-2.
Chaos. 2020 Aug;30(8):081104. doi: 10.1063/5.0015626.
9
So-called Urinary Tract Infection in the Era of COVID-19.
J Am Geriatr Soc. 2020 Sep;68(9):1927-1928. doi: 10.1111/jgs.16685. Epub 2020 Aug 13.
10
Angiotensin receptor blockers for the treatment of COVID-19 and its comorbidities.
Pharmacol Res. 2020 Sep;159:104958. doi: 10.1016/j.phrs.2020.104958. Epub 2020 May 28.
本文引用的文献
1
Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study.
Stroke Vasc Neurol. 2020 Sep;5(3):279-284. doi: 10.1136/svn-2020-000431. Epub 2020 Jul 2.
2
SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.
Cell. 2020 May 28;181(5):1016-1035.e19. doi: 10.1016/j.cell.2020.04.035. Epub 2020 Apr 27.
3
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
Cell. 2020 May 14;181(4):905-913.e7. doi: 10.1016/j.cell.2020.04.004. Epub 2020 Apr 24.
4
Neurological complications of coronavirus and COVID-19.
Rev Neurol. 2020 May 1;70(9):311-322. doi: 10.33588/rn.7009.2020179.
5
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.
JAMA Cardiol. 2020 Jul 1;5(7):825-830. doi: 10.1001/jamacardio.2020.1624.
6
COVID-19 and intracerebral haemorrhage: causative or coincidental?
New Microbes New Infect. 2020 Mar 27;35:100669. doi: 10.1016/j.nmni.2020.100669. eCollection 2020 May.
7
COVID-19 and stroke-A global World Stroke Organization perspective.
Int J Stroke. 2020 Jun;15(4):361-364. doi: 10.1177/1747493020923472. Epub 2020 Apr 29.
8
Angiotensin receptor blockers and COVID-19.
Pharmacol Res. 2020 Jun;156:104832. doi: 10.1016/j.phrs.2020.104832. Epub 2020 Apr 15.
9
Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study.
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261. doi: 10.1007/s00405-020-05965-1. Epub 2020 Apr 6.
10
The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science.
JAMA Cardiol. 2020 Jul 1;5(7):747-748. doi: 10.1001/jamacardio.2020.1329.
Zotero 插件